-
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA, January 6, 2025 GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced…
-
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, GA, December 9, 2024 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies…
-
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
ATLANTA, GA, November 26, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced…
-
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, GA, November 19, 2024 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies…
-
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024…
-
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, November 5, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company…
-
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
ATLANTA, GA, October 2, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced…
-
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Atlanta, GA, August 28, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
Registration Is Now Open for Tribe Public’s Webinar Event “Now Is Not the Time to Monkey(pox) Around” Featuring GeoVax Lab’s CEO
Company to provide a detailed overview of Mpox including commentary on the rapid spread and methods for control, treatment, and prevention Atlanta,…
-
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
Atlanta, GA, August 20, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine …
-
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, August 8, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology…